Cholinesterase inhibitors are a class of anti-dementia drugs commonly used to treat Alzheimer’s disease. As the name implies, these drugs work by blocking the enzyme (acetylcholinesterase) that breaks down the neurotransmitter acetylcholine. Acetylcholine is important in regulating memory, cognitive function, and alertness in the brain, so blocking its breakdown can help to improve these functions in people with Alzheimer’s disease. The two most commonly prescribed cholinesterase inhibitors are donepezil and rivastigmine. Donepezil is given once a day in tablet form and works by blocking the enzyme action that breaks down acetylcholine. Rivastigmine is a form of gel with a time release mechanism that delivers the drug over a sustained period and works similarly. Cholinesterase inhibitors improve the levels of acetylcholine in the brain, which in turn helps the patient to better remember things, think more clearly, and stay alert. Because these drugs can slow down the progression of Alzheimer’s disease, they are usually taken for long periods of time, even if the patient has not experienced any noticeable improvement. The most common side effects of cholinesterase inhibitors are nausea, vomiting, and diarrhea. Other potential side effects include weight loss, increased sensitivity to sunlight, involuntary muscle jerking (myoclonus), and headaches. People taking these drugs may also be more prone to seizures. Cholinesterase inhibitors are considered a first-line therapy for Alzheimer’s disease, as they have been proven to slow the progression of the disease over time. While they cannot change the underlying causes of the disease or reverse any of the damage that has already occurred, they can be an important part of a comprehensive treatment plan for managing the progression of Alzheimer’s disease.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States